Lonza Group Limited (Basel, Switzerland) has selected a site for a cGMP facility that will produce microbial biopharmaceuticals. The Visp complex (Switzerland) was selected over sites in Kourim, Czech Republic, and Portsmouth, New Jersey. Lonza will spend approximately USD 63 million to construct and operate the new contract manufacturing plant that will include a 15,000-litre and a 1500-litre fermenter.
The new facility will be capable of providing clinical trial phases, as well as commercial production by a versatile design that allows specialty equipment to be added. Construction could begin in early 2003 with a completion date scheduled for the fourth quarter of 2004. Visp is Lonza’s largest research, development, and production centre. Lonza employs 4900 people world-wide and has 13 facilities in six countries. Visp is the world leader in contract manufacturing of therapeutic ingredients and intermediates. Lonza reported USD 1.2 billion in sales for the year of 2001.
For more projects, subscribe to our Project Preview Newsletter
